REGENXBIO shares plunge 35% on FDA clinical hold for RGX-121
RGNX Regenxbio Inc
$8.06 -24.86%
View chart & analysis → - 1REGENXBIO (RGNX) shares plunge 35% after FDA clinical hold on Hunter syndrome gene therapy RGX-121
- 2Five CAMPSIITE participants were found to have asymptomatic nodules/cystic masses on spine MRI roughly 3–6 years post-administration; near-term BLA resubmission outlook withdrawn
- 3Findings are classified as non-serious and likely benign, with no abnormalities on brain MRI; the company will focus on its Duchenne and retinal programs
This 3-line summary is compiled from the report below.
InvestorsHub +1 View original ↗
오늘의 AI 픽 5종목, 무료로 전부 공개합니다숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다